Skip to content
Education Training, Medical Health Aged Care

Study shows how Instagram could help promote awareness of stuttering

Charles Darwin University 2 mins read

A study into Instagram posts about stuttering has revealed a significant gap of credible and reliable information about the speech disorder on the social media platform. 

The study by Charles Darwin University (CDU) and Michigan State University in the United States explored how stuttering is defined and understood on Instagram, and how users engaged with stuttering-related content.

The authors analysed 74 Instagram posts with the tag #Stuttering that received high engagement, made by a mix of: speech pathologists, people who stutter, a speech pathologist who stutters, a parent of a child who stutters, and news agencies or unknown accounts. 

The posts were analysed and grouped into varying themes, with one of the most prevalent themes being ‘positive meaning around people who stutter’. The results show audiences had positive attitudes towards stuttering content and people who stutter, suggesting stuttering is acceptable by many audiences and should be seen positively. 

CDU Lecturer - Speech pathologist and co-author Dr Hamid Karimi said while these results were encouraging, the authors identified opportunities to spread awareness and correct misinformation about stuttering.

The results show posts by news agencies drew the highest engagement, compared to the posts by individuals who stutter or speech pathologists, which had significantly lower engagement. 

“Notably, none of the posts analyzed in this study were published by recognized and reliable stuttering-related organizations, which have a track record of significantly contributing to public awareness about stuttering,” Dr Karimi said. 

The study found a trend of highly engaged-with posts using stuttering as a comic device, which could contribute to stuttering stigmas and be used to spread harmful misinformation and presentations of the speech disorder. 

“Such stigmas were more evident in political arguments and when stuttering was used as a comic device for entertainment,” Dr Karimi said.

“In these posts, people who stutter were presented as anxious people, less capable of performing well in more complex social roles and having ongoing challenges in different aspects of life, including their relationships with colleagues and friends.” 

Dr Karimi said the study showed reputable organisations should use Instagram as a tool to spread public awareness about stuttering. 

“Organisations should learn how to promote posts and how to have more of an impact on society,” Dr Karimi said. 

“Promoting posts about stuttering on Instagram and other social media platforms, especially on key occasions such as International Stuttering Awareness Day, could be a highly effective strategy.

“Such initiatives could counterbalance misinformation, raise public awareness about stuttering, and provide reliable resources for people who stutter and their families. This enhanced understanding of how stuttering is portrayed on social media platforms can inform and shape future outreach and awareness programs, thereby increasing their effectiveness and reach."

The study was published in the Journal of Fluency Disorders.  

Contact details:

Raphaella Saroukos she/her
Communications Officer
Marketing, Media & Communications
Larrakia Country
T: +61 8 8946 6721

More from this category

  • Medical Health Aged Care
  • 24/06/2024
  • 17:07
Takeda Pharmaceutical Company Limited

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

LIVTENCITY Is the First and Only Post-Transplant Anti-CMV Treatment Approved in Japan That Targets/Inhibits UL97 Protein Kinase1 CMV Is One of the Most Common…

  • Contains:
  • CharitiesAidWelfare, Medical Health Aged Care
  • 24/06/2024
  • 16:20
National Rural Health Alliance

Community-led innovation to revolutionise healthcare access in rural Australia

The National Rural Health Alliance (the Alliance) is delighted that the Minister for Health and Aged Care, the Hon Mark Butler, has today announced…

  • Contains:
  • Business Company News, Medical Health Aged Care
  • 24/06/2024
  • 12:25
Jane Morgan Management

Imugene (ASX:IMU) Doses First Patient in Pioneering Phase 1 onCARlytics Trial

Sydney, Australia, 24 June 2024: Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is thrilled to announce the dosing of the first patient in the intravenous (IV) infusion combination arm of its Phase 1 onCARlytics (CF33-CD19) clinical trial. This groundbreaking trial, named OASIS, is being conducted at City of Hope in California and is designed to transform the treatment landscape for patients with advanced solid tumors. The OASIS trial is a world-first, combining a CD19-expressing oncolytic virus with a CD19-targeting drug. The trial aims to recruit 40-45 patients with advanced solid cancers that have metastasized, with preliminary early combination data…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.